|
Video: What is a Stock Split?
|
|
Unity Biotechnology is a biotechnology company engaged in the research and development of therapeutics to slow, halt, or reverse diseases of aging. Co. focuses on creating senolytic medicines to selectively eliminate senescent cells and thereby treat diseases of aging, such as ophthalmologic diseases. Co.'s ophthalmology program includes UBX1325, which is its main drug candidate for age-related diseases of the eye including diabetic macular edema, age-related macular degeneration and diabetic retinopathy. Co.'s neurology program includes UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain. According to our Unity Biotechnology stock split history records, Unity Biotechnology has had 1 split. | |
|
Unity Biotechnology (UBX) has 1 split in our Unity Biotechnology stock split history database. The split for UBX took place on October 20, 2022. This was a 1 for 10 reverse split, meaning for each 10 shares of UBX owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split.
When a company such as Unity Biotechnology conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the Unity Biotechnology stock split history from start to finish, an original position size of 1000 shares would have turned into 100 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Unity Biotechnology shares, starting with a $10,000 purchase of UBX, presented on a split-history-adjusted basis factoring in the complete Unity Biotechnology stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
05/04/2018 |
|
End date: |
05/03/2024 |
|
Start price/share: |
$167.50 |
|
End price/share: |
$1.61 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-99.04% |
|
Average Annual Total Return: |
-53.87% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$96.16 |
|
Years: |
6.00 |
|
|
|
Date |
Ratio |
10/20/2022 | 1 for 10 |
|
|